СЛОВО,abstract,lysosomal,integral,membrane,protein-2,limp-2,encoded,by,the,scarb2,gene,is,specific,receptor,for,glucocerebrosidase,enzyme,association,between,rs6812193,and,rs68250047,of,with,pd,has,been,shown,in,genetic,studies,including,large,genome-wide,aim,current,study,was,to,determine,whether,rs8475,are,associated,russia,were,genotyped,a,total,604,patients,65,positive,fpd,539,negative,family,history,spd,413,controls,also,17,gba,mutations,pd-gba,18,asymptomatic,mutation,carriers,gba-carriers,expression,measured,real-time,pcr,cd45,blood,cells,part,individuals,studied,groups,no,linkage,disequilibrium,russian,population,increased,risk,tt,variant,or,,202,p,0001,found,but,not,age,at,onset,aao,level,decreased,gba-pd,compared,padjusted,002,0003,respectively,0013,significant,difference,modified,conclusion,status,modifier,do,influence,on,mrna,could,be,independent,buspirone,partial,agonist,5-ht1ar,due,potential,antinociceptive,properties,can,useful,abdominal,pain,treatment,ibs,pain-related,effects,mediated,5-ht1ars,located,within,nucleus,tractus,solitarius,involvement,transmission,nts,unclear,objective,our,evaluate,using,model,urethane-anesthetized,rats,two,types,neurons,responding,noxious,colorectal,distension,crd,excitatory,inhibitory,sustained,patterns,evoked,activity,revealed,10–40 mg kg−1,iv,complex,time-,dose-depended,action,crd-induced,neuron,responses,inhibits,inverts,dose,40,effect,attenuates,crd-evoked,completely,blocked,an,intra-cerebroventricular,administration,way100635,change,this,supraspinal,5-ht1a,receptors,however,its,does,dependents,these,we,proposed,that,involved,anti-,pronociceptive,background,microrna,mirnas,participate,pathogenesis,coronary,artery,disease,cad,expressions,myocardial,serum,mirna-27а,mirna-133а,mirna-203,method,cross-sectional,observational,comprised,100,subjects,609  10 years,67%,men,right,atrial,mirna-27a,mirna,-133a,80,referred,elective,bypass,graft,surgery,cabg,20,control,scheduled,heart,valve,analyzed,polymerase,chain,reaction,results,there,correlation,syntax,score,i,index,r  0693,p  001,≥3,lesions,had,significantly,higher,than,1–2,vessel,myocardium,23462  2951,vs,18239  1962,relative,unit,reu,12753  1341,11135  1231,525  096,471  067,р  005,same,1141  385,482  182,842  243,435  123,14571  1573,4370  967,decision,tree,established,multivessel,five-fold,if,10100,590,95%,ci,234–946,conclusions,both,non-cad,corresponds,strongly,correlated,extent,atherosclerosis,series,binuclear,pdii,carbene,complexes,synthesized,via,cis-pdcl2cnxyl2,1,benzo-13-thiazol-2-amines,2–6,structurally,characterized,every,case,leads,mixture,regioisomers,which,able,interconvert,regioisomerization,diaminocarbene,species,showed,it,first-order,occurs,intramolecularly,hammett,function,electron-withdrawing,substituents,benzothiazole,moiety,as,well,increasing,solvent,polarity,accelerate,donor,strength,correlates,less,isomerization,rates,based,obtained,activation,parameters,defined,interchange/dissociative,process,type,combined,approach,kinetic,mass,spectrometric,allowed,rate-determining,step,breaking,carbon–nitrogen,bond,fragment,aims,2,diabetes,mellitus,t2dm,ranks,top,10,causes,mortality,worldwide,key,factor,vascular,complications,endothelial,dysfunction,vessels,motor,disruption,endothelium-derived,factors,imbalance,morphological,molecular,heterogeneity,greatly,affects,changes,occurring,therefore,conducted,comparative,bed,main,methods,male,wistar,fed,high-fat,diet,20 weeks,followed,single,streptozotocin,injection,20 mg/kg,confirmed,oral,glucose,tolerance,test,findings,dose-dependent,contraction,increase,third-order,mesenteric,arterioles,response,serotonin,phenylephrine,exhibited,decrease,acetylcholine-dependent,relaxation,guanylate,cyclase,time,femoral,arteries,tendency,plasma,analysis,low,bioavailable,nitric,oxide,high,levels,endothelin-1,ros,significance,knowledge,conjunction,features,course,allow,further,targeted,approaches,development,prevention,lorlatinib,novel,potent,alk,inhibitor,only,few,reporting,clinical,use,describes,outcomes,35,non-small,cell,lung,cancer,rearrangements,who,n  5,n  26,none,n  4,prior,tyrosine,kinase,inhibitors,received,mainly,compassionate,program,tumor,dc,registered,15/35,43%,33/35,94%,brain,metastases,particularly,responsive,22/27,81%,27/27,100%,median,progression,free,survival,pfs,estimated,218,months,overall,os,approached,701,4,out,experienced,adverse,them,benefit,from,no-adverse-events,users,strikingly,lower,remaining,11,237,105,reached,00001,comparisons,translocation,variants,known,28,statistical,v1,v3,regard,excellent,caution,must,taken,experiencing,drug,three,bariatric,interventions,infarct,size,tested,rat,evaluated,no-reflow,phenomenon,caused,assigned,into,without,sham-operated,ileal,transposition,roux-en-y,gastric,sleeve,gastrectomy,glucagon-like,peptide-1,insulin,six,weeks,after,animals,subjected,ischemia-reperfusion,histochemical,determination,zone,stasis,area,wire,myography,all,reductions,animal,body,weight,resulted,compensation,partially,normalized,attenuated,smaller,provided,additional,limitation,alone,surgeries,reversed,t2dm-induced,enhanced,contractile,5-hydroxytryptamine,synthase,contribution,endothelium-dependent,vasodilatation,reduction,infarct-limiting,augmented,contractility,typical,together,suggest,may,have,beneficial,cardiovascular,diseases,present,investigates,event-related,oscillations,underlying,motion-onset,mor,sounds,moving,different,velocities,eeg,recorded,stationary,sound,motion,produced,interaural,differences,explored,velocity,spectral,perturbation,ersp,inter-trial,phase,coherence,itc,calculated,time-frequency,decomposition,signals,slow,similarly,magnitude,cn1,cp2,components,delta-to-alpha,power,remained,up,highest,suggesting,gradual,spatial,did,induce,non-coherent,conversely,abrupt,displacement,induced,theta-alpha,consistency,generated,resetting,degree,considered,neurophysiological,indicator,processing,currently,thought,full,glycogen,molecule,β-particle,spherical,shape,12,concentric,tiers,residues,glycogenin,center,diameter,about,42,nm,structure,remains,poorly,understood,β-particles,hepatocytes,starved,situ,cytofluorometry,technique,measurement,speed,staining,schiff's,reagent,measurements,molecules,quickly,stained,labile,fraction,lf,represents,internal,while,slowly,stable,sf,external,proteins,predicts,3rd,4th,42%,bound,7th,8th,19%,tier,never,amount,particle,surface,variable,thus,makes,possible,obtain,data,particular,eculizumab,terminal,complement,reduced,relapse,placebo,anti-aquaporin-4,immunoglobulin,g-positive,aqp4,neuromyelitis,optica,spectrum,disorder,nmosd,prevent,trial,report,efficacy,safety,analyses,asian,open-label,extension,ole,double-blind,randomized,3,randomly,21,receive,intravenous,maintenance,1200 mg/2,completed,performed,prespecified,subgroup,143,enrolled,52,364%,included,n  37,n  15,45,most,865%,concomitant,immunosuppressive,therapy,during,one,adjudicated,occurred,receiving,hazard,ratio,005,confidence,interval,001–035,p  00002,952%,relapse-free,144,upper,respiratory,tract,infections,headache,nasopharyngitis,common,events,reduces,benefit–risk,profile,similar,benefits,maintained,long-term,registration,clinicaltrialsgov,identifiers,nct01892345,nct02003144,task,identify,synchronization,intermittent,photic,stimulation,arterial,hypertension,manifestations,moderate,cognitive,impairment,such,solve,used,recurrence,instantaneous,frequencies,duration,synchrosqueezed,wavelet,transform,light,greater,manifested,photostimulation,bioelectric,shift,frequency,range,excitation,assessment,origin,migraine,sensitisation,trigeminovascular,system,often,accompanied,mechanical,hyperalgesia,allodynia,mechanisms,mechanotransduction,attack,yet,unknown,ion,channel,piezo1,since,expressed,trigeminal,ganglion,contribute,neuronal,component,took,advantage,extracellular,recordings,trigeminocervical,–,relay,centre,pathway,directly,assess,impact,differently,applied,yoda1,sensory,spinal,slightly,facilitated,ongoing,firing,central,substance,contributed,suppression,their,intravital,microscopy,dilation,meningeal,innervated,afferents,collectively,here,identified,modulation,selective,mechanosensitive,channels,provide,new,evidence,favour,role,propose,several,underlie,silica,silicon,dioxide,depending,production,exist,various,amorphous,forms,varying,pore,volume,result,physicochemical,sorption,characteristics,presence,silanol,silicas,provides,possibility,functionalisation,addition,developed,aerosil,allows,composites,content,biologically,active,substances,work,biocompatibility,composite,380,carboxylated,fullerene,c60ccooh23,namely,haemolysis,spontaneous,photoinduced,platelet,aggregation,binding,hsa,cyto-,genotoxicity,antiradical,interest,creation,nanomaterial,fact,fullerenes,applications,fields,biomedicine,ability,bind,reactive,oxygen,inhibition,tumour,inactivation,viruses,bacteria,immobilisation,drugs,theranostics,tnf-α,inflammatory,cytokine,stem,regions,carotid,bodies,organs,monitoring,o2,hypothesised,circulating,necrosis,affect,ventilation,modulate,hypoxic,ventilatory,cyclooxygenase,cox,nos,pathways,compare,before,pretreatment,diclofenac,l-ng-nitro,arginine,methyl,ester,l-name,nonspecific,anaesthetised,rebreathing,techniques,normoxia,hypoxia,each,believe,nos-related,cross-talk,mediates,underlies,inflammation,hla-haploidentical,transplantation,haplo-hct,post-transplantation-cyclophosphamide,pt-cy,feasible,procedure,children,malignancies,childhood,acute,lymphoblastic,leukemia,lacking,180,9,years,follow-up,27,cr1,24%,cr2,45%,cr3,12%,day,bone,marrow,bm,source,115,64%,cumulative,incidence,42-day,engraftment,889%,day-100,graft-versus-host,gvhd,grade,ii-iv,28%,2-year,chronic,219%,nonrelapse,nrm,196%,419%,25%,65%,44%,188%,transplanted,3%,year,multivariable,hr  219,p  04,hct,older,13,hr  207,p  03,peripheral,pbsc,hr  198,hr  313,option,those,remain,important,improved,summary,covid-19,pandemic,having,profound,mental,health,consequences,many,people,concerns,extreme,manifest,suicide,aimed,early,around,world,sourced,countries,areas,through,systematic,internet,search,recourse,networks,published,literature,sept,nov,2020,searched,official,websites,countries’,ministries,police,agencies,government-run,statistics,equivalents,translated,terms,cause,death,broadening,attempt,other,public,sources,given,country,they,came,government,available,monthly,least,jan,2019,july,31,searches,restricted,more,million,residents,pragmatic,reasons,relaxed,rule,populations,interrupted,time-series,trend,suicides,march,comparing,expected,number,derived,observed,april,primary,16,high-income,five,upper-middle-income,whole-country,ten,rate,ratios,rrs,cis,versus,numbers,began,any,south,wales,australia,rr,0·81,0·72–0·91,alberta,canada,0·80,0·68–0·93,british,columbia,0·76,0·66–0·87,chile,0·85,0·78–0·94,leipzig,germany,0·49,0·32–0·74,japan,0·94,0·91–0·96,zealand,0·79,0·68–0·91,korea,0·92–0·97,california,usa,0·90,0·85–0·95,illinois,cook,county,0·67–0·93,texas,four,counties,0·82,0·68–0·98,ecuador,0·74,0·67–0·82,interpretation,first,examine,context,multiple,largely,unchanged,declined,pre-pandemic,period,need,vigilant,poised,respond,situation,longer-term,economic,unfold,funding,hiv-positive,inject,pwid,experience,stigma,related,hiv,care,utilization,help,affected,cope,intersectional,reduce,adapted,behavioral,coping,intervention,conduct,controlled,rct,testing,‘stigma,risks,improve,treatment’,script,community-based,form,acceptance,commitment,act,living,st,petersburg,recruited,civil,society,organizations,cso,delivering,harm,services,participants,either,sessions,group,format,over,month,usual,psychological,flexibility,handle,stigma-related,expectations,emotions,experiences,satisfaction,scores,targeting,outside,formal,settings,confront,negativities,lives,originating,stigma's,barrier,encoding,gcase,gaucher,gd,commonly,parkinson,ambroxol,effective,pharmacological,chaperones,fourteen,thirty,hexosylsphingosine,hexsph,concentration,dried,macrophage,spots,liquid,chromatography,coupled,tandem,spectrometry,lysosomes,assessed,confocal,cultured,macrophages,patient,monocytic,pbmc,33-fold,35-fold,untreated,p  00001,days,cultivation,21-fold,16-fold,colocalization,marker,lamp2,modes,mutant,carrying,n370s,amino,acid,substitution,ph,47,examined,docking,dynamics,simulations,position,minimal,energy,close,vicinity,residue,370,pbmc-derived,assessing,rationale,hemodialysis,hd,kidney,replacement,availability,accessibility,affordability,quality,design,survey,setting,stakeholders,clinicians,policy,makers,consumer,representatives,182,convened,international,nephrology,september 2018,analytical,descriptive,160,88%,participated,country-specific,2984,iqr,805-5994,per,pmp,global,among,incident,failure,980,815-1408,centers,12–99,adequate,3-4,hours,times,weekly,generally,27%,low-income,home,36%,32%,patient-reported,61% monitoring,small-solute,clearance,60% monitoring,mineral,markers,51% monitoring,60%,initiation,dialysis,5%,arteriovenous,access,almost,education,suboptimal,procedures,uniform,copayments,income,23%,pay,75%,costs,4%,limitations,bias,social,desirability,limited,collection,preventing,in-depth,reveal,substantial,variations,lowest,evident,low-,lower-middle–income,prognosis,refractory,induction,chemotherapy,immunotherapy,dismal,salvage,allogeneic,hematopoietic,hsct,widely,10%,15%,cured,preclinical,indicate,post-transplantation,cyclophosphamide,bendamustine,ptb,prophylaxis,regimen,graft-versus-leukemia,gvl,establish,optimal,antileukemic,prospective,nct02799147,administered,doses,140,70,mg/m2,myeloablative,conditioning,fludarabine,busulfan,single-agent,subsequent,combination,tacrolimus,mycophenolate,mofetil,mmf,inclusion,criteria,myelogenous,aml,target,≥5%,clonal,blasts,cohort,22,5,seven,stopping,documented,41%,secondary,59%,blast,count,start,18%,6%,97%,matched,sibling,mismatched,unrelated,15,haploidentical,7,93%,89%,complete,remission,63%,measurable,residual,unusual,complication,release,syndrome,crs,70%,frequent,symptoms,fever,abnormal,liver,tests,pancreatitis,skin,vasculitis,56%,enterocolitis,48%,mucosa,37%,disseminated,intravascular,coagulation,nervous,toxicity,26%,hla-mismatched,20%,p  0043,classic,p  031,severe,100-day,survivors,immunosuppression,p  002,relatively,three-year,13%,46%,event-free,29%,11%,relapses,statistically,p  3481,mg/kg,35%,0%,p  0157,promising,augment,crs-associated,necessitates,routine,application,cannot,recommended,ameliorates,hla-matched,allografts,biological,require,elucidation,previous,diagnosed,schizophrenia,scz,deficits,visual,contrast,brain-derived,neurotropic,bdnf,measure,investigate,neuroplasticity,some,functions,like,perception,investigated,relationship,first-episode,thirty-nine,healthy,43,sensitivity,mid-,except,middle,correlations,variables,mostly,females,support,alterations,magno-,parvocellular,functioning,ii,highlights,importance,biomarkers,along,measures,disorders,purpose,analyze,5-year,biochemical,disease-free,bdfs,late,prostate,treated,pencil,beam,scanning,pbs,proton,radiation,materials,january,2013,2016,284,intensity,modulated,impt,ultrahypofractionated,schedule,3625,gye,fractions,immediately,lost,excluded,279,prospectively,collected,565,34-875,mean,645,401-857,prostate-specific,antigen,psa,value,635,μg/l,067-173,121,434%,low-risk,125,448%,favorable,33,118%,unfavorable,intermediate-risk,49,176%,underwent,neoadjuvant,hormonal,adjuvant,profiles,7-18,969%,917%,835%,terminology,v4,follows,gastrointestinal,62,22%,72%,036%,genitourinary,287%,14,0,61%,lymph,node,detected,14%,local,recurrences,nine,died,deaths,reported,comparable,fractionation,schedules,serious,gi,gu,cajal-retzius,transient,elements,developing,cerebral,cortex,express,characteristic,heavy-chain,neurofilaments,participating,construction,mature,believed,feature,human’s,stain,smi-32,antibody,non-phosphorylated,horizontally,oriented,soma,bipolar,processes,labeled,layer,cats,aged,0–2,postnatal,dii,well-developed,parallel,vertical,branches,coming,horizontal,visualized,location,general,morphology,allowing,suppose,carnivores,share,primates,developmental,corticogenesis,recent,decades,semiconductor,lasers,successfully,rhinology,usage,nasal,swell,nsb,barely,research,experimental,selection,laser,exposure,mode,970 nm,diode,safe,thermometric,wavelength,continuous,contact,2 w,10 w,cattle,optical,region,experiments,temperature,4 w,demonstrate,causing,thermal,damage,adjacent,tissue,experiment,breathing,hypertrophy,39,vasomotor,rhinitis,divided,consisted,laser-turbinectomy,19,pathology,dynamic,observation,respiration,according,anterior,rhinomanometry,when,subgroups,t-criterion,samples,p  005,nose,scale,student's,t-test,p  0001,perform,subjectively,noted,insufficiency,indicates,regulation,airflow,trace,amine-associated,taars,class,g,protein-coupled,detect,biogenic,amines,products,decarboxylation,acids,majority,taar2-taar9,described,olfactory,epithelium,sensing,innate,odors,members,taar5,limbic,projection,mouse,line,knockout,taar5-ko,mice,beta-galactosidase,mapping,dopamine,striatal,metabolites,gdnf,elevated,indicating,proliferation,furthermore,major,neurogenic,subventricular,svz,subgranular,sgz,potentially,surrounding,ventricle,direct,neurogenesis,doublecortin,dcx,proliferating,nuclear,pcna,2-fold,observations,emotional,adult,future,antagonists,exert,antidepressant,and/or,anxiolytic,opportunity,neurodegenerative,parkinson's,hemispheric,asymmetry,erps,low-frequency,oscillatory,hemispheres,stimuli,delayed,computed,read,books,choice,passive,listening,indicated,trajectories,perceived,graphic,tablet,goal,find,lateralization,consistent,right-hemispheric,dominance,contralateral,neglect,interhemispheric,apparent,hemisphere,stronger,contralaterality,left,corresponding,delta-alpha,attention,consistently,how,pattern,interrelated,motion-related,single-trial,antibodies,aquaporin-4,water,trigger,cascade,implicated,astrocyte,injury,demonstrated,anti-aqp4,reducing,across,clinically,relevant,time-to-event,adults,1200 mg/2 weeks,stable-dose,ist,permitted,rituximab,mitoxantrone,post,hoc,demographic,autoimmune,comorbidity,sex,race,historical,annualized,baseline,expanded,disability,another,infection,regardless,wide,tris-malonate,c60,cf,great,studying,plants,primarily,malonate,means,improving,crop,yield,water-soluble,derivatives,physiological,plant,state,enough,paper,devoted,growth,netto,productivity,salad,tomatoes,spring,barley,wheat,initial,stages,seed,germination,vegetative,following,absorption,assimilation,capacity,roots,aerial,parts,moisture,entering,distributing,containing,physiologically,organic,compounds,cyclic,catabolism,optimising,antioxidant,shows,indicators,seedling,condition,solutions,ccf  0001–01,mg·dm−3,approximately,peritoneal,practice,globe,delivery,outcome,n160,313,257,nephrologists,82%,non-nephrologist,physicians,7%,6,professionals,2%,administrators/policy,makers/civil,servants,others,85%,n156,responded,questions,381,30,156,pd-related,africa,20/41,15/22,69%,modality,for≤10%,newly,1%,out-of-pocket,expenses,incurred,asia,average,exchange,volumes,exchanges,equivalent,automated,explanations,underpinning,lack,granular,inter-,intraregional,disparities,greatest,gaps,effectiveness,regimens,dydrogesterone,management,endometriosis-related,pelvic,twenty,gynecology,clinics,federation,hundred,fifty,women,endometriosis,dysmenorrhea,mg,daily,5th,25th,menstrual,cycle,prolonged,cyclical,continuously,cutoff,11-point,numerical,rating,marked,standard,deviation,–33,–30,improvements,analgesics,required,severity,sexual,well-being,health-related,quality-of-life,a favorable,reactions,pronounced,led,life,nct03690765,los,regímenes,de,tratamiento,didrogesterona,cíclicos,y,continuos,prolongados,son,efectivos,para,reducir,el,dolor,pélvico,crónico,en,mujeres,con,resultados,del,estudio,orchidea,objetivo,comparar,la,efectividad,dos,diferentes,manejo,relacionado,diseño,cohortes,prospectivo,observacional,durante,seis,meses,entorno,veinte,clínicas,ginecológicas,federación,rusa,pacientes,trescientas,cincuenta,entre,años,edad,o,sin,dismenorrea,intervenciónes,ó,veces,al,día,bien,días,25,ciclo,menestrual,régimen,cíclico,prolongado,ininterrumpido,continuo,todas,las,se,limitó,recogida,datos,medidas,resultado,principales,intensidad,una,escala,puntuación,numérica,puntos,tras,observó,marcada,reducción,tanto,como,cambio,nivel,basal,medio,desviación,estándar,-33,-30,respectivamente,diferencia,significativa,ambos,grupos,experimentaron,mejoras,significativas,número,que,requirieron,analgésicos,severidad,bienestar,parámetros,calidad,vida,relacionados,salud,confirmó,un,perfil,seguridad,informó,reacciones,adversas,severas,medicación,conclusiónes,demostraron,pronunciada,resultaron,marcadas,todos,estudiados,strategies,needed,optimise,surgical,resection,early-stage,non-small-cell,nsclc,atezolizumab,best,supportive,platinum-based,impower010,randomised,multicentre,done,227,sites,eligible,resected,stage,ib,tumours,≥4,cm,iiia,union,internationale,contre,le,american,joint,committee,staging,edition,permuted-block,block,1200,cycles,regular,scans,endpoint,investigator-assessed,hierarchically,ii–iiia,whose,pd-l1,sp263,then,finally,intention-to-treat,itt,ib–iiia,nct02486718,recruiting,oct,2015,2018,1280,1269,whom,1005,randomisation,n507,n498,495,32·2,27·4–38·3,hr,0·66,0·50–0·88,p0·0039,0·64–0·96,p0·020,0·67–0·99,p0·040,atezolizumab-related,53,offers,f,hoffmann-la,roche,genentech,genetics,buspirone-dependent,mechanism,diaminocarbenepdii,region-specific,tone,opposite,acetylcholine,carcinomas,distinct,single-center,cytochemical,anti-aquaporin-igg-positive,estimation,differential,electrophysiological,nanocomposite,mediate,unmanipulated,post-transplant,pediatric,trends,preliminary,addressing,increases,restores,patient-derived,parkinsonism,dose-ranging,cancer-5-year,labeling,feline,auditory
ВСТРЕТИЛОСЬ_РАЗ_в_2021,33,4,1,1,1,1,1,36,443,8,4,46,5,2,71,4,4,5,16,7,295,1,360,142,27,4,5,6,280,3,8,8,4,1,3,2,37,92,131,1,2,8,19,12,5,70,1,101,2,1,115,1,3,2,1,4,2,3,2,1,6,13,3,5,4,1,4,1,1,1,3,13,4,3,1,2,9,13,1,3,7,8,21,1,1,2,14,11,11,1,1,39,17,1,2,1,6,11,20,7,31,3,2,8,6,5,12,3,1,1,8,1,9,5,2,6,7,1,2,2,45,2,8,19,3,9,1,5,3,6,6,1,3,7,1,5,14,23,1,5,14,2,1,2,9,2,2,2,2,5,7,1,10,9,5,25,8,1,11,6,4,14,2,1,1,1,1,4,6,1,8,4,11,6,1,1,4,1,1,3,1,2,15,1,1,8,1,13,1,1,2,1,28,1,1,1,3,32,1,1,6,9,12,1,1,15,35,3,33,7,1,1,7,1,1,1,3,5,5,24,2,5,8,8,2,5,9,5,5,2,2,6,3,1,4,1,2,2,4,3,1,2,1,1,2,2,9,2,3,4,1,1,1,4,1,1,6,16,6,1,1,2,2,4,1,2,1,2,9,5,7,8,1,1,1,1,8,1,1,1,7,1,1,1,1,2,4,1,1,1,1,1,1,1,1,1,1,1,3,1,1,9,7,1,5,9,1,1,1,1,2,1,3,4,1,2,3,1,3,1,13,1,1,1,6,3,1,1,1,1,8,1,1,3,1,2,7,7,1,1,1,1,6,1,1,1,1,23,5,2,2,1,1,5,1,2,3,2,3,10,4,6,4,2,1,1,7,1,3,1,2,1,1,1,2,1,1,1,1,3,12,4,4,16,1,1,4,2,4,4,6,4,13,3,2,3,3,1,1,1,3,1,1,4,1,1,1,8,4,1,2,1,1,3,9,1,1,3,1,1,1,2,1,1,1,1,2,4,5,2,2,7,1,1,9,1,3,1,13,1,1,1,2,2,2,1,1,8,2,3,1,1,14,7,1,5,5,9,9,1,1,2,1,1,2,2,1,5,2,1,5,3,7,3,1,4,3,9,1,4,9,24,1,13,2,1,7,6,11,2,9,1,1,2,1,2,1,1,3,11,3,1,1,1,2,2,1,1,1,1,10,1,2,1,1,1,1,2,13,1,4,16,3,5,1,13,6,3,1,1,4,2,2,8,4,3,30,1,1,1,4,1,6,1,1,1,1,1,4,3,2,1,2,1,1,1,1,1,1,3,1,2,6,8,5,4,9,2,3,4,3,1,2,4,3,5,1,1,1,1,1,2,2,2,2,1,5,3,20,2,1,1,2,1,6,1,6,1,1,20,1,1,3,1,3,1,2,3,1,1,3,3,1,2,1,2,3,1,1,2,3,2,2,2,12,1,2,1,1,3,3,10,13,1,1,1,4,2,3,6,1,2,8,2,1,3,1,5,2,1,9,9,2,2,4,1,4,3,2,3,3,18,5,2,1,2,2,3,2,1,1,1,1,2,1,4,3,1,1,1,1,8,4,2,1,1,1,1,1,1,1,1,1,3,2,1,1,7,2,1,1,8,4,2,1,1,3,1,5,5,1,1,1,2,1,1,5,1,1,1,1,2,2,2,2,5,1,1,1,1,1,2,4,1,2,1,2,1,3,1,1,1,1,1,2,4,1,3,1,1,2,2,1,3,1,1,1,2,5,2,6,1,3,2,17,2,18,2,3,3,12,8,1,2,2,8,4,4,4,6,8,14,10,1,3,6,4,10,5,3,3,2,6,18,3,6,4,1,4,1,1,4,2,8,2,6,1,1,5,1,1,4,9,1,5,2,16,5,8,2,3,4,2,3,1,2,2,1,1,1,1,1,1,7,1,1,1,1,4,5,2,1,3,7,2,2,3,3,3,1,2,1,2,2,6,3,2,2,3,2,2,4,3,3,4,1,8,4,1,4,2,2,2,2,3,2,1,1,1,1,3,6,1,2,1,4,1,4,8,2,1,1,1,1,4,1,1,1,1,1,2,5,3,7,2,1,1,3,1,1,1,1,1,1,1,1,1,2,1,2,6,1,2,5,3,1,1,1,1,1,2,5,1,1,9,2,3,1,1,1,1,1,1,2,1,1,1,1,4,5,4,1,1,1,1,1,1,1,1,1,1,2,4,1,1,1,1,1,2,1,1,2,2,1,1,1,2,1,2,2,3,1,1,1,1,7,2,1,2,2,2,7,6,7,3,1,1,1,1,1,3,1,1,1,1,2,1,1,2,2,1,1,1,2,1,1,1,1,5,1,1,1,1,4,1,8,1,2,4,2,1,1,3,4,1,1,1,1,1,2,1,2,3,2,3,2,3,2,3,2,1,1,1,1,1,1,1,1,1,1,1,1,6,1,1,1,1,1,2,1,4,4,1,5,1,2,3,1,1,9,3,7,2,1,2,6,4,1,5,1,5,1,2,1,3,5,3,2,4,1,2,5,5,1,2,1,1,3,6,12,2,2,2,10,1,2,2,1,1,4,1,4,1,2,1,3,1,1,3,1,2,1,1,1,1,2,1,1,4,2,2,2,2,3,5,8,3,1,3,10,3,1,4,1,1,1,8,4,5,2,2,2,34,8,3,1,2,3,1,3,1,2,2,1,4,1,2,1,1,1,1,2,1,3,1,1,1,2,1,1,1,7,1,1,2,5,1,1,1,4,2,5,2,2,4,3,1,1,8,4,1,1,2,1,2,1,2,2,1,5,2,3,5,8,2,12,1,7,2,4,2,2,1,1,6,1,1,1,9,2,1,1,4,1,1,1,2,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,3,1,1,1,1,3,1,1,1,1,1,1,1,6,1,1,1,1,1,1,2,3,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,3,3,2,4,1,8,3,7,15,1,3,2,2,3,5,3,1,3,4,2,2,2,1,1,1,2,1,1,1,2,1,1,3,2,3,3,1,1,3,1,3,1,1,2,5,3,1,7,1,2,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,2,1,9,2,6,1,1,8,5,1,1,1,1,1,2,3,1,2,1,1,1,1,1,1,1,1,1,1,3,6,1,1,1,1,1,4,8,1,1,1,1,1,1,1,2,2,1,2,1,2,1,1,2,1,1,1,2,2,1,1,1,1,1,1,1,2,2,10,4,1,5,5,5,8,4,5,5,2,2,3,3,1,3,2,2,4,2,2,2,2,1,2,1,1,1,4,1,4,3,2,3,1,3,1,1,1,1,2,2,1,2,1,2,1,4,1,1,2,2,1,1,1,1,1,3,1,1,1,4,3,1,3,1,1,1,1,1,2,1,1,2,3,2,2,2,2,1,1,2,1,1,2,1,1,1,1,1,2,1,1,6,2,8,1,1,1,1,1,2,1,1,1,1,1,2,2,2,2,9,4,3,1,3,1,2,1,2,1,1,1,2,2,4,1,2,1,1,2,2,3,2,1,1,2,1,2,1,4,1,1,1,1,2,7,8,1,1,5,1,1,1,1,1,1,2,1,1,2,1,1,2,1,2,2,1,1,3,1,2,1,1,1,2,1,1,5,1,1,1,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,5,2,1,1,1,1,1,2,1,1,2,1,1,1,2,3,1,1,3,2,3,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,3,2,2,7,1,8,4,1,1,5,2,2,1,2,1,1,1,1,1,5,1,2,1,3,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,5,2,1,1,2,1,5,4,3,6,3,1,2,1,1,4,3,1,1,1,1,1,3,1,1,3,1,1,1,1,1,1,1,1,1,2,1,1,2,1,1,1,2,2,1,1,2,1,1,1,1,1,1,3,1,1,2,3,1,1,3,1,2,11,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,3,1,1,1,4,1,1,4,1,1,1,2,3,2,1,2,2,1,1,1,1,1,1,1,2,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,5,2,11,1,1,1,1,7,3,4,4,4,1,2,1,5,2,2,1,1,1,2,1,1,1,2,1,2,2,1,1,1,2,1,1,1,1,1,1,2,2,1,1,2,1,3,1,1,1,5,1,1,1,1,3,1,1,1,1,1,1,1,1,3,1,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,9,1,1,1,1,2,3,5,2,1,5,2,1,1,1,1,1,1,1,2,1,2,1,2,2,2,2,1,3,1,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,1,2,1,4,1,1,3,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,3,1,1,2,1,2,2,2,2,1,1,1,1,1,1,3,1,1,1,1,2,1,1,1,1,1,1,1,1,2,1,3,4,2,2,1,1,1,1,4,1,4,1,2,2,1,3,1,1,1,1,1,2,1,1,2,2,1,1,1,1,1,1,1,7,1,1,1,1,1,1,1,1,2,3,2,1,1,1,1,1,1,1,1,1,1,1,2,1,2,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,3,1,2,4,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,2,1,1,1,1,2,1,1,1,1,1,1,5,1,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,5,5,1,1,7,1,1,1,1,1,1,2,5,3,3,1,1,1,1,1,4,4,1,1,1,1,1,2,1,1,1,1,2,1,1,2,4,2,1,1,1,1,2,1,1,1,5,4,26,6,5,1,12,1,2,1,1,2,1,5,7,7,7,9,2,9,2,6,3,2,1,1,9,1,1,1,1,1,1,1,1,1,2,2,3,1,1,1,1,1,1,3,1,1,3,1,1,2,2,3,1,1,1,2,1,1,2,1,1,1,3,3,2,1,3,1,2,5,1,1,1,1,1,1,2,3,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,1,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,2,4,8,6,6,2,4,2,2,1,1,1,2,4,9,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,6,3,3,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1
